Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

Part of Osteoporosis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Postmenopausal Osteoporosis

60 trials tracked for Postmenopausal Osteoporosis: 41 in phase 3 or 4 and 13 with published results. The most-cited published study has 596 citations.

60Trials tracked
41Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 14 Phase 3 27 Phase 2 8 Phase 1 5 Other / NA 6
  1. Phase 4 VERtebral Fracture Treatment Comparisons in Osteoporotic Women Completed · 596 cited
  2. Phase 3 An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women Completed · 485 cited
  3. Phase 3 Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis Completed · 206 cited
  4. Phase 3 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis Completed · 170 cited
  5. Phase 4 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis Completed · 161 cited
  6. Phase 4 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed · 70 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed · 48 cited
  2. Phase 3 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Completed · 41 cited
  3. Phase 3 A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis Completed · 28 cited
  4. Phase 3 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis Completed · 23 cited
  5. Phase 3 A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis Completed · 12 cited
  6. Phase 4 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed · 8 cited
  7. Phase 3 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND Completed · 3 cited
  8. Phase 4 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed
  9. Phase 4 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed
  10. Phase 4 The Effects of Potassium Citrate on Bone Metabolism Completed
  11. Phase 4 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed
  12. Phase 4 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Completed
  13. Phase 4 Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) Completed
  14. Phase 4 Preventing Osteoporosis Using Denosumab Completed
  15. Phase 4 A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide Completed
  16. Phase 4 Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) Completed
  17. Phase 4 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed
  18. Phase 3 Denosumab China Phase III Study Completed
  19. Phase 3 A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis Completed
  20. Phase 3 A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis Completed
  21. Phase 3 A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis Completed
  22. Phase 3 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Completed
  23. Phase 3 A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis Completed
  24. Phase 3 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® Completed
  25. Phase 3 A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  26. Phase 3 Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis Completed
  27. Phase 3 A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women Completed
  28. Phase 3 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates Completed
  29. Phase 3 A Study of Monthly Risedronate for Osteoporosis Completed
  30. Phase 3 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  31. Phase 3 Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women Completed
  32. Phase 3 Study of Transitioning From Alendronate to Denosumab Completed
  33. Phase 3 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab Completed
  34. Phase 3 Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis Completed
  35. Phase 3 A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Completed
  36. Phase 2 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women Completed
  37. Phase 2 Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) Completed
  38. Phase 2 Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women Completed
  39. Phase 2 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed
  40. Phase 2 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed
  41. Phase 2 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Completed
  42. Phase 2 Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women Completed
  43. Phase 2 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Completed
  44. Phase 1 A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Postmenopausal Osteoporosis: what the trials found

New clinical evidence identifies ENZ215 as a treatment for postmenopausal osteoporosis 1.

Teriparatide significantly reduces the incidence of new vertebral fractures (p=0.000094), pooled new and worsening vertebral fractures (p=0.000075), and pooled clinical vertebral and non-vertebral fragility fractures (p=0.000869) 2.

Denosumab is associated with significant increases in spine bone mineral density (BMD) 4 and improvements in total hip BMD 6 and spine BMD 6.

Romosozumab demonstrates significant efficacy in reducing the incidence of new vertebral fractures at 12 months (p<0.001) and 24 months (p<0.001), as well as clinical fractures at 12 months (p=0.008) 18. It also significantly increases BMD at the lumbar spine, total hip, and femoral neck [16, 21].

Abaloparatide is associated with significant increases in mineralizing surface/bone surface (MS/BS) in the cancellous envelope 20, as well as significant increases in lumbar spine, total hip, and femoral neck BMD at 12 months 22.

Alendronate combinations show significant improvements in lumbar spine BMD at both 6 and 12 months 13 and significantly higher gains in total hip, femoral neck, and lumbar spine BMD compared to other cohorts 17. Alendronate with cholecalciferol was associated with a reduction in patients with serum 25-hydroxyvitamin D below deficiency levels (p<0.0001) and significant changes in Serum PTH 15.

Ibandronate is associated with high patient adherence rates (98.5%) and high scores in patient satisfaction surveys 11. Patients also showed a preference for once-monthly dosing over once-weekly dosing based on convenience of administration (p<0.0001) 9.

Placebo groups showed significant increases in lumbar spine BMD compared to other cohorts at 6 and 12 months 12, while a separate placebo study showed significantly lower rates of new vertebral fractures compared to an intervention group 19.

Recent results — preliminary, needs further review

  • ENZ215 is identified as a new treatment for postmenopausal osteoporosis 1.

For the clinician treating this condition

  • Teriparatide, Romosozumab, and Abaloparatide are associated with significant reductions in fracture incidence or substantial increases in bone mineral density across multiple sites.
  • Denosumab and Alendronate (with various co-treatments) provide statistically significant improvements in spine and hip BMD.
  • Ibandronate is associated with high patient satisfaction and adherence, particularly when administered in a once-monthly dosing regimen.

AI synthesis of 14 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women
Diabetes & Endocrinology Cohort
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women Better nutrition linked to lower osteoporosis risk in women with diabetes
This retrospective observational cohort study of 324 postmenopausal women with type 2 diabetes found that a higher Geriatric Nutritional Ris…
A simple nutrition score may help spot osteoporosis risk in women with type 2 diabetes, new hospital data suggests.
Frontiers Apr 22, 2026

Research across Osteoporosis

Related studies from across the Osteoporosis family.

Coumarins and derivatives may protect musculoskeletal health by modulating inflammatory and oxidative mediators
Nutrition & Obesity Medicine Meta-analysis
Coumarins and derivatives may protect musculoskeletal health by modulating inflammatory and oxidative mediators Coumarins may protect bone and joint health in several diseases
This systematic review examines the role of coumarins and their derivatives in managing musculoskeletal diseases including osteoporosis, rhe…
Coumarins and their derivatives may slow the progression of bone and joint diseases by targeting inflammation and specific cellular pathways…
Frontiers Sep 12, 2026
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation
Orthopedics & Sports Medicine Meta-analysis
Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation Potent bisphosphonates may lower fracture risk after denosumab treatment stops
This meta-analysis of 683 adults with osteoporosis or low bone mass found that potent bisphosphonate therapy significantly reduced incident …
Patients with osteoporosis may have a lower risk of spine fractures when switching to potent bisphosphonates after stopping denosumab.
NEJM Sep 6, 2026
CDAI and SDAI scores improve prediction of osteoporosis in patients with rheumatoid arthritis
Rheumatology Guideline
CDAI and SDAI scores improve prediction of osteoporosis in patients with rheumatoid arthritis New scores help identify osteoporosis risk in rheumatoid arthritis patients
This guideline provides a cross-sectional analysis of osteoporosis prediction in patients with rheumatoid arthritis. The authors found that …
Specific disease-activity scores can help doctors better identify osteoporosis risk in patients living with rheumatoid arthritis.
Frontiers Aug 30, 2026
Senolytics like dasatinib and quercetin show promise for improving skeletal parameters in osteoporosis models
Diabetes & Endocrinology Sys. Review
Senolytics like dasatinib and quercetin show promise for improving skeletal parameters in osteoporosis models Senolytics Show Potential for Improving Bone Health in Osteoporosis
This narrative review synthesizes preclinical and early clinical evidence regarding senolytics including dasatinib, quercetin, and fisetin f…
New research explores how senolytics like dasatinib and quercetin may reduce inflammation and improve bone health in patients with osteoporo…
Frontiers Aug 25, 2026
Nutrition-related laboratory biomarkers provide risk stratification for geriatric patients with hip fractures
Nutrition & Obesity Medicine Sys. Review
Nutrition-related laboratory biomarkers provide risk stratification for geriatric patients with hip fractures Nutrition markers may help predict recovery after hip fractures
This narrative review synthesizes the role of nutrition-related laboratory indicators, such as serum albumin and prealbumin, in predicting o…
Up to 46% of elderly patients with hip fractures suffer from malnutrition, which can impact their recovery and long-term health outcomes.
Frontiers Aug 22, 2026
Pharmacist-led medication therapy management improves adherence and glycemic control in a patient with complex T2DM
Rheumatology Sys. Review
Pharmacist-led medication therapy management improves adherence and glycemic control in a patient with complex T2DM Pharmacist-led care improves blood sugar for woman with long-term diabetes
This case report describes a single patient with type 2 diabetes who received pharmacist-led medication therapy management. The intervention…
A pharmacist-led review helped a woman with a 30-year history of Type 2 Diabetes significantly improve her medication adherence and blood su…
Frontiers Aug 21, 2026
Indole derivatives regulate bone homeostasis via gut-bone axis in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Indole derivatives regulate bone homeostasis via gut-bone axis in osteoporosis Indole derivatives may help manage bone health in osteoporosis
This systematic review synthesizes evidence that indole derivatives can regulate bone homeostasis through the gut-bone axis, involving gut m…
A new review explores how indole derivatives might protect bones by improving the connection between gut health and bone stability.
Frontiers Aug 21, 2026
CircRNAs demonstrate high diagnostic accuracy for osteoporosis with an AUC of 0.91
Diabetes & Endocrinology Meta-analysis
CircRNAs demonstrate high diagnostic accuracy for osteoporosis with an AUC of 0.91 New blood markers show promise in detecting bone loss
This meta-analysis of 14 independent studies evaluated circRNAs as biomarkers for osteoporosis compared to DXA-derived bone mineral density.…
A new type of genetic marker called circRNA shows high accuracy in identifying patients with osteoporosis during early screening.
Frontiers Aug 18, 2026
Curcumin raises femoral bone density in animal osteoporosis models, meta-analysis finds
Diabetes & Endocrinology Meta-analysis
Curcumin raises femoral bone density in animal osteoporosis models, meta-analysis finds Curcumin shows potential to improve bone density in animal models
This meta-analysis of 23 preclinical studies in animal models of osteoporosis found that curcumin monotherapy significantly increased femora…
New research suggests that curcumin may help strengthen bones and protect against osteoporosis in early laboratory studies.
Frontiers Aug 12, 2026
Glucocorticoid use and rheumatoid arthritis significantly increase vertebral fracture risk in postmenopausal women
Rheumatology Meta-analysis
Glucocorticoid use and rheumatoid arthritis significantly increase vertebral fracture risk in postmenopausal women Several risk factors increase fracture risk for women with osteoporosis
This meta-analysis of 11 studies involving 7,605 participants identifies several risk factors for vertebral fractures in postmenopausal wome…
Women with rheumatoid arthritis or those using certain medications face a much higher risk of spine fractures.
Frontiers Aug 4, 2026
Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management
Orthopedics & Sports Medicine Sys. Review
Bibliometric Mapping Analysis Reveals Evolving Research Trends in Scoliosis and Osteoporosis Management Scoliosis and Osteoporosis Research Trends Mapped Over 20 Years
A comprehensive bibliometric analysis of over 1,000 publications highlights a significant shift toward bone quality assessment and risk stra…
A new review maps 20 years of scoliosis and osteoporosis research, revealing a shift toward bone quality and surgical outcomes.
Frontiers Jul 25, 2026
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis
OB/GYN & Women's Health Sys. Review
Gut microbiota interventions may modulate bone metabolism and influence progression of postmenopausal osteoporosis Gut bacteria may help prevent osteoporosis in older women
This systematic review explores how gut microbiota-based interventions, including probiotics and prebiotics, may impact bone health in postm…
A new review suggests probiotics and other gut-focused treatments could help protect bone health in postmenopausal women.
Frontiers Jul 4, 2026